Premium
Long‐term treatment of hypercholesterolemia with colestipol hydrochloride
Author(s) -
Ryan Jerome R.,
Jain Adesh K.,
McMahon F. Gilbert
Publication year - 1975
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt197517183
Subject(s) - placebo , constipation , gastroenterology , medicine , bile acid , anesthesia , alternative medicine , pathology
Colestipol hydrochloride (15 gm/day) (an anion exchange resin that binds bile acids) or placebo was administered to 92 patients with hypercholesterolemia who were followed for periods up to 36 months. There was a prompt (1 month), significant (p < 0.05‐0.001), and sustained (36 months) lowering of serum cholesterol in the colestipol HCl‐treated group, but no significant change in the placebo group. Serum triglycerides increased in both treatment groups in parallel; the reason was not apparent. Side effects were equally distributed between colestipol HCI and placebo and were primarily gastrointestinal (upper abdominal distress, constipation). Colestipol HCI appears to be a safe and effective treatment for hypercholesterolemia; tolerance does not seem to develop.